.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD02_MetforminAndSulfonylurea.MetforminAndSulfonylurea .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD02_MetforminAndSulfonylurea.MetforminAndSulfonylurea| name: | MetforminAndSulfonylureas |
| ATC code: | A10BD02 | route: | oral |
| n-compartments | 1 |
Combination products containing metformin (a biguanide antihyperglycemic agent) and sulfonylureas (insulin secretagogues) are used to treat type 2 diabetes mellitus. These combinations leverage complementary mechanisms: metformin decreases hepatic glucose production and increases insulin sensitivity, while sulfonylureas stimulate insulin release from pancreatic beta cells. Such combinations are approved and widely used as oral diabetic medications.
Pharmacokinetic parameters estimated for adult patients with type 2 diabetes. No published clinical PK model specific for the fixed drug combination found; parameters presented as estimated from individual component literature for typical oral dosing.
Kirchheiner, J, et al., & Brockmöller, J (2005). Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 44(12) 1209–1225. DOI:10.2165/00003088-200544120-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16372821
Jirapure, K, & Undale, V (2022). Antidiabetics Interactions with Herbs: A Compressive Review. Current diabetes reviews 18(1) e011221190237–None. DOI:10.2174/1573399817999210112191718 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33438541
Huang, X, et al., & Chen, L (2023). Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. Clinical pharmacology in drug development 12(5) 509–517. DOI:10.1002/cpdd.1219 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36642944